These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30910278)

  • 41. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 43. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unmet Needs in LDL-C Lowering: When Statins Won't Do!
    Krähenbühl S; Pavik-Mezzour I; von Eckardstein A
    Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
    Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A
    Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
    Taylor BA; Thompson PD
    Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological management of diabetic dyslipidemia.
    Filippatos TD; Florentin M; Georgoula M; Elisaf MS
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):187-200. PubMed ID: 27868450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined lipid-lowering therapy.
    Karásek D
    Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of dyslipidemia in kidney transplantation.
    Ponticelli C; Arnaboldi L; Moroni G; Corsini A
    Expert Opin Drug Saf; 2020 Mar; 19(3):257-267. PubMed ID: 32073914
    [No Abstract]   [Full Text] [Related]  

  • 58. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].
    Bubnova MG; Kukharchuk VV
    Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
    Fazio S
    Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.